Key issues for vertical agreements in the life sciences sector

This year has seen a number of significant changes to the EU and UK competition regimes, particularly in relation to vertical agreements.  These changes have the potential to affect existing and new agreements in the life sciences sector, and divergences between the EU and UK approaches may increase complexity for companies with multi-national operations.  The life sciences sector has long been at the top of EU and national (including UK) authorities’ priority list given its importance to governments and patients – changes to the competition regimes should therefore be high on companies’ watch lists.

Do you like what you are reading?

Please log-in or register to access Engage and set your preferences

New to Engage?

Create a free account for access to this publication and our vast catalogue of legal updates

Already Registered?

Log-in to continue reading



This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.